Regarding the molecular pathogenesis and genetic alterations in hepatocellular carcinoma, all of the following statements are correct EXCEPT:

Explanation

## Molecular Pathogenesis of HCC ### Key Genetic Alterations in HCC **Mnemonic:** **TP53-CTNNB1-TERT-AXIN** — the major driver mutations in HCC | Gene/Pathway | Frequency | Mechanism | Prognostic Impact | |---------------|-----------|-----------|-------------------| | **TP53** | 20–50% | Loss of tumor suppressor; p53 inactivation | Poor prognosis, aggressive behavior | | **CTNNB1 (β-catenin)** | 20–40% | Wnt pathway activation; nuclear accumulation | Variable; often associated with well-differentiated HCC | | **TERT promoter** | >50% | Telomerase reactivation; unlimited replication | Early event; poor prognosis | | **AXIN1** | 5–15% | Wnt pathway regulation; loss of function | **Significant contributor** to tumorigenesis | | **APC** | Rare in HCC | Wnt pathway suppressor | Minimal role in HCC | ### TP53 Mutations **High-Yield:** TP53 is mutated in 20–50% of HCCs (not the single most common — TERT promoter mutations are more frequent). TP53 mutations are strongly associated with: - Poor prognosis - Aggressive phenotype - Resistance to therapy - Higher recurrence rates ### CTNNB1 (β-Catenin) Pathway **Clinical Pearl:** CTNNB1 mutations activate the **Wnt/β-catenin signaling pathway**, leading to: - Constitutive pathway activation - Nuclear accumulation of β-catenin - Transcription of proliferation genes - Found in 20–40% of HCCs - Often (but not always) associated with better differentiation ### TERT Promoter Mutations **Key Point:** TERT promoter mutations occur in **>50% of HCCs** — the **most frequent genetic alteration**. They: - Enable telomerase reactivation - Allow unlimited replicative potential - Represent an **early event** in hepatocarcinogenesis - Are found in dysplastic nodules and early HCC - Associated with poor prognosis ### AXIN1 and APC in HCC **High-Yield:** - **AXIN1** mutations occur in **5–15% of HCCs** and are **significant contributors** to tumorigenesis via Wnt pathway dysregulation - **APC** mutations are **rare in HCC** (unlike in colorectal cancer) and do **not play a major role** in HCC pathogenesis ### Why Option 3 is Correct Option 3 states that AXIN1 and APC mutations are rare and do not contribute significantly. While APC mutations are indeed rare in HCC, **AXIN1 mutations occur in 5–15% of cases and DO contribute significantly** to HCC pathogenesis through Wnt pathway dysregulation. The statement incorrectly groups AXIN1 with APC and underestimates AXIN1's role.